Publicaciones en las que colabora con José Luis Lanciego Pérez (23)

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2016

  1. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

    Biomaterials, Vol. 110, pp. 11-23

2014

  1. GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells

    Hippocampus, Vol. 24, Núm. 7, pp. 733-739

2012

  1. Loss of parvalbumin-positive neurons from the globus pallidus in animal models of parkinson disease

    Journal of Neuropathology and Experimental Neurology, Vol. 71, Núm. 11, pp. 973-982

2011

  1. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease

    Movement Disorders, Vol. 26, Núm. 10, pp. 1943-1947

2010

  1. Production of highly pure human glycosylated GDNF in a mammalian cell line

    International Journal of Pharmaceutics, Vol. 385, Núm. 1-2, pp. 6-11

2009

  1. Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson's disease

    Journal of Controlled Release, Vol. 135, Núm. 2, pp. 119-126

  2. Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors

    Journal of Biological Chemistry, Vol. 284, Núm. 41, pp. 28058-28068

  3. The search for a role of the caudal intralaminar nuclei in the pathophysiology of Parkinson's disease

    Brain Research Bulletin, Vol. 78, Núm. 2-3, pp. 55-59

2008

  1. Controlled drug delivery to the brain: an overview

    Handbook of particulate drug delivery (American Scientific Publishers), pp. 121 - 142

  2. Expression of vesicular glutamate transporters 1 and 2 in the cells of origin of the rat thalamostriatal pathway

    Journal of Chemical Neuroanatomy, Vol. 35, Núm. 1, pp. 101-107

  3. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 69, Núm. 3, pp. 844-851

2007

  1. Detection of two different mRNAs in a single section by dual in situ hybridization: A comparison between colorimetric and fluorescent detection

    Journal of Neuroscience Methods, Vol. 162, Núm. 1-2, pp. 119-128

  2. Expression of the mRNAs encoding for the vesicular glutamate transporters 1 and 2 in the rat thalamus

    Journal of Comparative Neurology, Vol. 501, Núm. 5, pp. 703-715

  3. Microencapsulación de factores neurotróficos: Aplicación al tratamiento de la enfermedad de Parkinson

    Mapfre Medicina, Vol. 18, Núm. 4, pp. 240-248

  4. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor

    International Journal of Pharmaceutics, Vol. 344, Núm. 1-2, pp. 9-15

2006

  1. 'Functional' neuroanatomical tract tracing: Analysis of changes in gene expression of brain circuits of interest

    Brain Research, Vol. 1072, Núm. 1, pp. 91-98

  2. Consequences of unilateral nigrostriatal denervation on the thalamostriatal pathway in rats

    European Journal of Neuroscience, Vol. 23, Núm. 8, pp. 2099-2108

  3. Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson

    Anales del sistema sanitario de Navarra, Vol. 29, Núm. 3, pp. 325-335

2005

  1. Intralaminar thalamic nuclei are main regulators of basal ganglia - Possible involvement in the pathophysiology of Parkinson's disease

    Basal Ganglia VIII